Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis - Scorecard - MDSpire
Advertisement
Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis
Clinical Scorecard: Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis
At a Glance
Category
Detail
Condition
Atopic Dermatitis (AD)
Key Mechanisms
Baricitinib is a selective JAK1/JAK2 inhibitor used for treating moderate-to-severe AD.
Target Population
Adults aged ≥ 18 years with moderate-to-severe atopic dermatitis.
Care Setting
Dermatology departments of 13 hospitals across Spain.
Key Highlights
Baricitinib persistence rates were 85.1%, 75.7%, and 58.4% at weeks 16, 24, and 52, respectively.
By week 16, 69.7% of patients achieved a ≥ 75% improvement in EASI (EASI75).
79.3% reached an IGA score of 0 or 1 by week 16.
The study provides real-world evidence of baricitinib's effectiveness in AD management.
Patients experienced significant improvements in quality of life indicators.
Guideline-Based Recommendations
Diagnosis
Confirm diagnosis of moderate-to-severe atopic dermatitis through clinical assessment.
Management
Consider baricitinib as a treatment option for adults with moderate-to-severe AD who are candidates for systemic therapy.
Monitoring & Follow-up
Monitor AD severity using EASI and IGA scores at regular follow-up visits.
Risks
Assess for potential adverse effects associated with baricitinib treatment.
Patient & Prescribing Data
Adults with moderate-to-severe atopic dermatitis in Spain.
Baricitinib can be administered as monotherapy or in conjunction with topical corticosteroids.
Clinical Best Practices
Ensure informed consent is obtained for data collection and treatment.
Utilize validated assessment tools like EASI and IGA for monitoring treatment effectiveness.
Evaluate patient history for previous AD treatments before initiating baricitinib.
by Enrique Gómez de la Fuente, Enrique Herrera, Iñigo Martinez-Espronceda Esquerdo, David Vidal Sarró, Ignasi Figueras-Nart, Juan F. Silvestre Salvador, Yolanda Gilaberte, Sergio Santos Alarcón, Esther Serra-Baldrich, Monica Munera Campos, Rosa M. Moro, Silvia Díaz-Cerezo, Sebastian Moyano, Irene Talavera-Rodríguez, Mercedes Núñez
